Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model
暂无分享,去创建一个
A. Fagan | D. Holtzman | B. Hyman | S. Paul | M. Irizarry | K. Bales | Bradley T. Hyman | Kelly Bales | L. Sartorius | David M. Holtzman | Anne M. Fagan | Brian Mackey | Tanya Tenkova | Leah Sartorius | Steven M. Paul | Karen Hsiao Ashe | Michael C. Irizarry | B. Mackey | K. Hsiao Ashe | T. Tenkova | Brian Mackey | Leah J. Sartorius
[1] R. E. Pitas,et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. , 1987, The Journal of biological chemistry.
[2] A. Fagan,et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. Ghetti,et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.
[4] B. Sommer,et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[5] A. M. Saunders,et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.
[6] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[7] D. Borchelt,et al. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. , 1997, Human molecular genetics.
[8] M. Lalowski,et al. Is Alzheimer's disease an apolipoprotein E amyloidosis? , 1995, The Lancet.
[9] J. D. Olmos,et al. A modified cupric-silver technique for the impregnation of degenrating neurons and their processes , 1981, Brain Research.
[10] J. Olney,et al. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning , 1996, Brain Research.
[11] B. Hyman,et al. Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .
[12] M. A. Neumann. COMBINED AMYLOID VASCULAR CHANGES AND ARGYROPHILIC PLAQUES IN THE CENTRAL NERVOUS SYSTEM , 1960, Journal of neuropathology and experimental neurology.
[13] Mark J. West,et al. New stereological methods for counting neurons , 1993, Neurobiology of Aging.
[14] Thomas Wisniewski,et al. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.
[15] H. Brewer,et al. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.
[16] A. Fagan,et al. Glial Fibrillary Acidic Protein–Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and apoE4 Lipoproteins , 1998, The Journal of Neuroscience.
[17] R. Wetzel,et al. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. , 1996, Biochemistry.
[18] Bradley T. Hyman,et al. Apolipoprotein E ε4 Is Associated With the Presence and Earlier Onset of Hemorrhage in Cerebral Amyloid Angiopathy , 1996 .
[19] D. Graham,et al. High frequency of apolipoprotein E ϵ2 Allele in hemorrhage due to cerebral amyloid angiopathy , 1997, Annals of neurology.
[20] R N Kalaria,et al. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. , 1996, The American journal of pathology.
[21] L. Thal,et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant , 1996, Neurology.
[22] E. Otomo,et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.
[23] B. Hyman,et al. APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.
[24] J. Poirier,et al. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. , 1999, Brain research. Molecular brain research.
[25] H. Vinters. Cerebral amyloid angiopathy. A critical review. , 1987, Stroke.
[26] S. Paul,et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.
[27] B. Tycko,et al. The apolipoprotein ε4 allele in patients with Alzheimer's disease , 1993, Annals of neurology.
[28] A. Fagan,et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. , 1999, The Journal of clinical investigation.
[29] D. Holtzman,et al. Nascent Astrocyte Particles Differ from Lipoproteins in CSF , 1998, Journal of neurochemistry.
[30] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[31] Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. , 1999 .
[32] J. Hardy,et al. Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family , 1994, Neuroscience Letters.
[33] B. Hyman,et al. Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.
[34] A. Roses,et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. , 1994, The Journal of clinical investigation.
[35] M. Tabaton,et al. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] B. Hyman,et al. Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse , 1997, The Journal of Neuroscience.
[37] P. Lansbury,et al. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[39] D. Borchelt,et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.
[40] R. Martins,et al. Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner , 1999, Neuroscience.
[41] J. Growdon,et al. Structure and Functions of Human Cerebrospinal Fluid Lipoproteins from Individuals of Different APOE Genotypes , 1998, Experimental Neurology.
[42] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[43] M. Mesulam,et al. β-Amyloid and the pathogenesis of alzheimer's disease , 1991 .
[44] R. Motter,et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .
[45] B. Permanne,et al. Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. , 1997, Biochemical and biophysical research communications.
[46] G. Glenner,et al. Differences Between Vascular and Plaque Core Amyloid in Alzheimer's Disease , 1988, Journal of neurochemistry.
[47] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[48] S. Paul,et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[49] C. Wernstedt,et al. Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain , 1995, Neuron.
[50] S. Greenberg,et al. Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy , 1998, Neurology.
[51] J. Breslow,et al. Apolipoprotein E and the apolipoprotein E-deficient mouse. , 1995, Annual review of nutrition.
[52] T. Wisniewski,et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. , 1995, The Biochemical journal.
[53] D. Selkoe,et al. Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging , 1988, Brain Research.
[54] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[55] Khadija Iqbal,et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. , 1993, Archives of biochemistry and biophysics.
[56] M J Ball,et al. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.